Daiichi Sankyo

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This large Phase 3 trial is testing whether a newer targeted drug, trastuzumab deruxtecan (Enhertu), combined with chemotherapy and possibly the immunotherapy pembrolizumab (Keytruda), works better than the current standard treatment for advanced HER2-positive stomach or gastroes…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive either I-DXd or a treatment chosen by their doctor. The g…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard treatments like platinum chemotherapy and immunotherapy. About 510 adults will be randomly assigned to receive either I-DXd or a standard ch…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…

This early-phase trial is testing a new drug called DS-1103a combined with an existing cancer drug, Enhertu, in people with advanced solid tumors that have a specific genetic marker (HER2). The study aims to find a safe dose and see if the combination shrinks tumors. About 108 ad…

This phase 3 trial tests whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy after surgery for HER2-positive endometrial cancer. About 710 adults with early-stage or locally advanced disease will be randomly assigned to receive T-DXd o…

This study is for people with advanced bladder cancer that has gotten worse after standard treatment. It tests a new drug combination (datopotamab deruxtecan plus chemotherapy) against another chemotherapy combo. The goal is to see if the new combo can shrink tumors or slow the c…

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.

This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…

This phase 3 trial tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy can delay cancer progression better than bevacizumab alone in people with HER2-expressing advanced ovarian cancer. About 582 adults whose cancer has a specific prote…

This study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …

This phase 3 trial is testing trastuzumab deruxtecan (T-DXd), a drug that delivers chemotherapy directly to cancer cells with a specific marker (HER2). It includes 250 people with advanced breast cancer that has low or even no HER2, which is often harder to treat. Participants re…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-stage trial tests an oral drug called DS9051b in 40 people with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for any signs that the drug might shrink t…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) combined with standard immunotherapy (atezolizumab) and sometimes chemotherapy (carboplatin) for people with extensive-stage small cell lung cancer who have not yet been treated. The goal is to see if the combinatio…

This study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study offers continued access to the cancer drug T-DXd for up to 50 people with advanced or metastatic cancer who are already benefiting from it in earlier trials. Researchers will monitor long-term safety, including serious side effects and reasons for stopping or reducing …

This study is observing over 2,500 adults with high cholesterol who are taking a combination of bempedoic acid and ezetimibe in routine medical care. Researchers are collecting data on side effects and heart risk to better understand how the treatment works in Asian and Latin Ame…

This study looks at how the cancer drug quizartinib behaves in people with severe liver impairment compared to healthy volunteers. Twelve participants will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor for side effects. The goal is…

This study follows up to 30 adults with tenosynovial giant cell tumor (TGCT) who had liver test abnormalities while taking TURALIO. The goal is to track long-term liver failure risk and understand how the drug may cause liver injury. Participants will be monitored after stopping …